生命科学资讯

Chutes & Ladders—Sarepta CEO to step down as DM1 hits close to home

FDA slams ExThera with warning letter over controversial blood filter device

Generate scores largest biotech IPO since 2024 with $400M Nasdaq listing

Thermo Fisher unveils test to aid in dosing of antirejection drug

Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs

Spatial Biomarker Panels for Clinical Trials

As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress

'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process

Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies

Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial

Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases

Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial

Quantum Surgical snaps up J&J's NeuWave Medical for its microwave ablation technology

Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits

Accent halts solid tumor trial over adverse events, pivots to other lead cancer program

Asahi Kasei scoops up Germany's Aicuris for $920M in R&D portfolio boost

ARPA-H designates up to $144M for anti-aging medical research

Worried Trump's MFN push will ‘destroy biotech innovation,’ midsize companies form coalition to fight back

Charles River sells manufacturing and discovery businesses to fulfill promised pivot

Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess